Author: Dalmeet Singh Chawla

Author loses five papers, most for “compromised” peer review

PLOS OnePLOS ONE has retracted three papers after the first author admitted to submitting the manuscripts without co-authors’ consent, and an investigation suggested that two out of the three papers had received faked reviews.

Last August, the same author — Lishan Wang of the Shanghai Jiao Tong University — lost two more papers (one in Tumor Biology and the other in Gene), also after the peer review process was found to be compromised. All five papers — which share other authors in common — were originally published in 2013, and four list Wang as the first author. The retractions follow an investigation by Shanghai Jiao Tong University.

Here’s the retraction notice for two of the PLOS ONE papers, issued on July 26: Continue reading Author loses five papers, most for “compromised” peer review

Authors retract study with contaminated cell lines

MBoCAuthors of a molecular biology paper have pulled it after realizing that their cell lines were contaminated.

According to the notice in Molecular Biology of the Cell (MBoC), the contamination occurred by “unknown means” in the senior authors’ laboratory, who told us the mistake was a difficult one to catch. He added that they discovered the problem after other researchers published conflicting results.

He also noted that the contaminated cell lines were not used for experiments in any other papers.

Here’s the retraction notice, issued on August 1: Continue reading Authors retract study with contaminated cell lines

Second retraction for bone researcher with lifetime funding ban

via WCH
via WCH

A researcher banned from funding by a Canadian agency for misconduct has earned her second retraction, after a reanalysis uncovered problems with the paper’s conclusions.

The retraction follows an investigation by Sophie Jamal‘s former workplace, the Women’s College Hospital in Toronto, which has led to a recent retraction of a JAMA paper due to data manipulation, and a lifetime funding ban from the Canadian Institutes of Health Research (CIHR).

The latest retraction stemmed from a re-analysis of the paper by the Canadian Multicentre Osteoporosis Study Group, of which the paper was a part; all authors but Jamal have requested the retraction. In the notice, the authors say that they believe no patients were harmed as a result of the “possibly invalid conclusions” in the paper, which showed patients with kidney problems were at higher risk of bone loss. A researcher told us a third paper by Jamal is also due to be retracted soon.

Here’s the retraction notice, issued by the American Journal of Kidney Diseases (AJKD): Continue reading Second retraction for bone researcher with lifetime funding ban

Journal flags two papers by prominent diabetes researcher, more questioned on PubPeer

DiabetesDiabetes has issued two expressions of concern (EOCs) for papers co-authored by leading diabetes researcher Kathrin Maedler, adding to her previous count of one retraction and three corrections.

Both papers were questioned on PubPeer, alongside several others co-authored by Maedler, who is based at the University of Bremen in Germany. As we previously reported, PubPeer comments have led to one retraction for Maedler in the Journal of Biological Chemistry (JBC), and corrections in various other journals.

One of those corrections has now earned an EOC from Diabetes, which also extends to the original paper. Here are the notices, which asks the University of Bremen to investigate further:  Continue reading Journal flags two papers by prominent diabetes researcher, more questioned on PubPeer

Seven retractions for prominent cancer researcher brings total to 18

Bharat Aggarwal
Bharat Aggarwal

A cancer researcher has earned seven more retractions following an investigation into his work by his former employer, MD Anderson Cancer Center in Texas, bringing his total to 18 retractions.

Bharat Aggarwal‘s name will be familiar to some readers, as he has threatened to sue Retraction Watch for reporting on his case.

All of the new retraction notices, issued by The Journal of Biological Chemistry (JBC), stem from image-related issues. The now-retired Aggarwal has seven papers that have each been cited at least 1,000 times, and in 2015, he was on Thomson Reuters Web of Science’s list of The World’s Most Influential Scientific Minds. With these new notices, he also has made it to our leaderboard of individual researchers who’ve racked up the most retractions.

An MD Anderson spokesperson sent us this statement: Continue reading Seven retractions for prominent cancer researcher brings total to 18

Beleaguered plant scientist with 22 corrections avoids 3 more

CellCell will not be issuing corrections for three papers co-authored by prominent plant biologist Olivier Voinnet, after readers on PubPeer raised questions about some of the images. 

The news may be a welcome relief for Voinnet, based at ETH Zurich in Switzerland, who has recently issued 22 corrections and seven retractions. Ongoing questions about his work have also earned him a three-year funding ban, and caused the European Molecular Biology Organization to revoke an award.

On July 28, Cell published editorial notes for all three papers, which have been collectively cited more than 1000 times (also reported by Leonid Schneider). The notes say that the journal will take “no further action,” noting that the authors of the papers informed Cell of the problems with figures, which do not appear to compromise the papers’ overall validity.  

Here’s the first editorial note, for a 1998 paper: Continue reading Beleaguered plant scientist with 22 corrections avoids 3 more

UK doctor banned from practice after fabricating data in grant applications

Queen Mary University of LondonA prominent cancer researcher in England has been banned from practicing medicine and has lost his funding from a UK charity after being found to have fabricated data in grant applications.

The moves against the researcher, Thorsten Hagemann, come after investigations by the General Medical Council, akin to a U.S. state medical board, and Hagemann’s former institution, Queen Mary University of London (QMUL), turned up evidence of misconduct. In June, we reported on the retraction of a meeting abstract in The Journal of Pathology and the corrigendum of a Nature paper by Hagemann following the inquiry at QMUL.

A spokesperson from the Medical Practitioners Tribunal Service told the Evening Standard: Continue reading UK doctor banned from practice after fabricating data in grant applications

Cell Press dismisses fraud allegations in high-profile genetics papers

Screen Shot 2016-08-03 at 18.54.35Cell Press has dismissed accusations of image manipulation in two well-cited papers. 

In June 2015, we reported that the publisher was investigating anonymous allegations of more than a dozen instances of manipulation of images in the papers published in Cell and Molecular Cell in 1999 and 2001, respectively. 

After assessing the original high-resolution versions of images from the laboratory notebook of Maria Pia Cosma, the first author of both papers, the journals have not found enough evidence to determine that fraud had occurred. 

Here’s the editorial note, issued last week for both papers (and also reported by Leonid Schneider): Continue reading Cell Press dismisses fraud allegations in high-profile genetics papers

PLOS ONE’s correction rate is higher than average. Why?

PLOS One

When a high-profile psychologist reviewed her newly published paper in PLOS ONE, she was dismayed to notice multiple formatting errors.

So she contacted the journal to find out what had gone wrong, especially since checking the page proofs would have spotted the problem immediately. The authors were surprised to learn that it was against the journal’s policy to provide authors page proofs. Could this partly explain PLOS ONE’s high rate of corrections?

Issuing frequent corrections isn’t necessarily a bad thing, since it can indicate that the journal is responsive to fixing published articles. But the rate of corrections at PLOS ONE is notably high. Continue reading PLOS ONE’s correction rate is higher than average. Why?

Biologist with five-year funding ban earns 7th and 8th retractions

Biology OpenA biologist in New Jersey has retracted two more papers, bringing his total to eight retractions, following a finding by the U.S. Office of Research Integrity (ORI).

The analysis of the work of John Pastorino, previously a cell biologist at Rowan University, in Glassboro, concluded that he had doctored more than 40 images, resulting in a five-year funding ban.

The report flagged eight published papers (and an unpublished one), six of which had already received expressions of concern (EOCs). Nataly Shulga was a co-author on all eight papers. With these two new retractions in Biology Open and Biochimica et Biophysica Acta (BBA) – Bioenergetics, all of the flagged papers have now been retracted.

Here’s the retraction notice for the Biology Open paper, issued July 15:

Continue reading Biologist with five-year funding ban earns 7th and 8th retractions